Podcasts about Cardiology

This week we review the results of the new pivotal trial of the 'Minima' stent by Renata Medical. What is special about this new device that makes it particularly desirable for use in small children? How strong is cobalt chromium and what evidence exists that it can be expanded repeatedly over 1-2 decades? Can this technology supplant surgery for certain diseases such as native coarctation? What are the limitations of this device? We speak with the first author of the pivotal trial, Dr. Patrick Sullivan of CHLA who is Associate Professor of Pediatrics at Keck Medicine at USC. DOI: 10.1161/CIRCINTERVENTIONS.125.015618

Dr. Matthew Budoff discusses Preventative Cardiology with moderator Dr. Ben Weitz at the Functional Medicine Discussion Group meeting on September 25, 2025. This was the second annual Dr. Howard Elkin memorial Preventative Cardiology lecture. [If you enjoy this podcast, please give us a rating and review on Apple Podcasts, so more people will find The Rational Wellness Podcast. Also check out the video version on my WeitzChiro YouTube page.] Podcast Highlights Dr. Matthew Budoff is a professor of medicine at the David Geffen School of Medicine at UCLA, Program Director and Director of Cardiac-CT, Division of Cardiology, Harbor-UCLA Medical Center and he is an investigator with The Lundquist Institute https://lundquist.org/matthew-budoff-md. Dr. Budoff's research is devoted to advancing procedures that can help doctors identify patients early that are at high-risk for cardiac events and progression of atherosclerosis. This early detection can lead to patients being placed on the correct therapeutic path to prevent a heart attack. Additionally, Dr. Budoff's research focuses on determining the effect of different therapies on atherosclerosis and determine if heart disease can be reversed. His office is in Torrance, California and his office number is 310-222-2773. Dr. Ben Weitz is available for Functional Nutrition consultations specializing in Functional Gastrointestinal Disorders like IBS/SIBO and Reflux and also Cardiometabolic Risk Factors like elevated lipids, high blood sugar, and high blood pressure. Dr. Weitz has also successfully helped many patients with managing their weight and improving their athletic performance, as well as sports chiropractic work by calling his Santa Monica office 310-395-3111.

WXPR News for 10-28-25

The PREVENT score in hypertension, GLP-1 mechanism of action in cardiovascular disease, CAD type and statin benefit, and the problem with hospitalization endpoints in HF trials are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Is the PREVENT Calculator Best for Determining CVD Risk? Insights From a Post Hoc Analysis of SPRINT Trial https://www.medscape.com/viewarticle/prevent-calculator-best-determining-cvd-risk-insights-post-2025a1000svo PREVENT Calculator https://doi.org/10.1016/j.jacc.2025.07.037 SPRINT Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1511939 II GLP-1 Mechanism of Action in CV Disease Analysis of SELECT Trial 10.1016/S0140-6736(25)01375-3 External Link SELECT trial https://www.nejm.org/doi/full/10.1056/NEJMoa2307563 III Statins and CAD Phenotype on CTA and Outcomes Interactions Between Statin Use, CAD Phenotypes on CTA  https://www.jacc.org/doi/10.1016/j.jcmg.2025.05.018 Statin Use for Primary Prevention of CVD https://jamanetwork.com/journals/jama/fullarticle/2795522 IV HHF Endpoints in Heart Failure Trials The Problem with Hospitalization Endpoints in HF Trials https://onlinelibrary.wiley.com/doi/10.1002/ejhf.70070 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

This week we review a recent survey study assessing the beliefs of fetal cardiologists and how these may influence the content and conduct of their counseling. Do most fetal cardiologists review all options including intervention, comfort care and pregnancy termination? Should there be a mandate that all do? Is it realistic or appropriate to ask a fetal cardiologist to suggest an option when they do not believe it to be a reasonable or correct choice? We speak with two of the authors of this work and they are Dr. Joanne Chiu of Harvard University and Dr. Caitlin Haxel of The University of Vermont. DOI: 10.1002/pd.6706

A new European Society of Cardiology clinical consensus statement deals with cardiovascular disease prevention and management in COVID-19, including cardiac long COVID. The report's lead author, Vassilios Vassiliou, MBBS, PhD, MA, discusses the guidance and key questions that remain about COVID-19 and the heart. Related Content: New Guidance on Cardiovascular Disease and COVID-19—From Infection to Long COVID to Vaccination

Surgeon's Secret Camera Captured Wife's Affair; Now I'm Head of Cardiology & FreeBecome a supporter of this podcast: https://www.spreaker.com/podcast/true-cheating-wives-and-girlfriends-stories-2025-true-cheating-stories-podcast--5689182/support.

This episode covers: Cardiology This Week: A concise summary of recent studies Arrhythmias in cardiac amyloidosis Taking the 'O' out of HOCM: managing LVOT obstruction Snapshots Host: Susanna Price Guests: Carlos Aguiar, Stephanie Schwarting, Ahmad Masri Want to watch that episode? Go to: https://esc365.escardio.org/event/2176 Want to watch that extended interview on Arrhythmias in Cardiac Amyloidosis? Go to: https://esc365.escardio.org/event/2176?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Ahmad Masri has declared to have potential conflicts of interest to report: research grants from Pfizer, Ionis, Attralus, Cytokinetics and Janssen. Consulting fees from Cytokinetics, BMS, BridgeBio, Pfizer, Ionis, Lexicon, Attralus, Alnylam, Haya, Alexion, Akros, Edgewise, Rocket, Lexeo, Prothena, BioMarin, AstraZeneca, Avidity, Neurimmune, and Tenaya. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Stephanie Schwarting has declared to have potential conflicts of interest to report: advisory board for Alnylam, Bayer, Pfizer; principal investigator in trials sponsored by Alexion, Novo Nordisk and Intellia. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Susanna Price Guest: Stephanie Schwarting Want to watch the episode? Go to: https://esc365.escardio.org/event/2176 Want to watch the extended interview on Arrhythmias in Cardiac Amyloidosis? Go to: https://esc365.escardio.org/event/2176?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests:  Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Stephanie Schwarting has declared to have potential conflicts of interest to report: advisory board for Alnylam, Bayer, Pfizer; principal investigator in trials sponsored by Alexion, Novo Nordisk and Intellia. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Surgeon's Secret Camera Captured Wife's Affair; Now I'm Head of Cardiology & FreeBecome a supporter of this podcast: https://www.spreaker.com/podcast/true-cheating-wives-and-girlfriends-stories-2025-true-cheating-stories-podcast--5689182/support.

In patients with heart failure, remote hemodynamic monitoring can identify health changes long before symptoms appear, contributing to slower disease progression, improved patient outcomes, and reduced rehospitalizations. Learn more about current and future technology that can support better patient health, and the role of nurses in patient education and monitoring. Guests: Linda Park, PhD, MS, FNP-BC, FAAN, FAHA, FPCNA, and Eryn Bryant, MSN, APRN-CNP, FPCNA.PCNA Heart Failure Tools: https://pcna.net/health-topics/heart-failure/Tele-HF study: https://www.jacc.org/doi/10.1016/j.jchf.2015.07.017 CHAMPION Trial (CMEMs after CRT): Pulmonary Artery Pressure-Guided Management of Patients With Heart Failure and Reduced Ejection Fraction https://www.acc.org/latest-in-cardiology/clinical-trials/2015/12/29/12/44/championJournal of American College of Cardiology paper, Remote Monitoring and Heart Failure Scientific Statement: https://www.jacc.org/doi/10.1016/j.jacc.2023.04.010 European Society of Cardiology consensus statement: https://doi.org/10.1093/eurheartjsupp/suae116BMAD trial: BMAD Trial: Wearable Remote Monitor Reduces Hospital Readmission Risk in HF Patients - American College of Cardiology: https://www.acc.org/Latest-in-Cardiology/Articles/2023/03/01/22/45/mon-830am-bmad-acc-2023 GUIDE-HF trial (CMEMS, Lancet): Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial - The Lancet: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01754-2/abstractESCAPE trial (using RHC / pulm art pressures to guide therapy during ADHF: Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial - PubMed: https://pubmed.ncbi.nlm.nih.gov/16204662/MONITOR-HF trial (improved QOL and functional status w/ CMEMs): Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial - The Lancet: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00923-6/abstract MONITOR-HF: Pulmonary artery pressure monitoring in chronic heart failure: effects across clinically relevant subgroups in the MONITOR-HF trial | European Heart Journal | Oxford Academic: https://academic.oup.com/eurheartj/article/45/32/2954/7668040MONITOR-HF (summary in ACC): Remote Hemodynamic Monitoring of Pulmonary Artery Pressures in Patients With Chronic Heart Failure - American College of Cardiology: https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2023/07/18/17/21/monitor-hfHeartLogic: HeartLogic Multisensor Algorithm Identifies Patients During Periods of Significantly Increased Risk of Heart Failure Events: https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.117.004669SCALE-HF-1 Trial (bodyport scale to predict worsening HF trends): Use of a Cardiac Scale to Predict Heart Failure Events: Design of SCALE-HF 1 | Circulation: Heart Failure: https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.122.010012See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

With Jean-Benoit Le Polain de Waroux, St-Jan Hospital, Brugge - Belgium, and Maarten De Smet, AZ Sint Jan, Brugge - Belgium.  Link to European Heart Journal paper Link to European Heart Journal editorial

Send us a textToday we are releasing another bonus episode! This is my recent appearance on the IFixHearts YouTube Channel, hosted by Chris S. Cornell!As always, it was a fun chat, and I'm always so grateful to be a guest on someone else's show!Find I Fix Hearts by Dr. Ovadia at-YT- @I Fix Hearts by Dr. OvadiaFind Boundless Body at- myboundlessbody.com Book a session with us here!

Tackle High-Yield Concepts for USMLE Step 2 CK Cardiology This interactive session, led by Dr. Abraham Titus (Hematology/Oncology Fellow, University of South Alabama) and ScholarRx’s Jeff Downing, focuses on challenging USMLE Step 2 CK cardiology questions that will sharpen your clinical decision-making skills and deepen your understanding of cardiovascular medicine. WHAT YOU’LL LEARN: In this episode, we work through four board-style questions using our proven systematic approach that helps you think like a clinician first, then a test-taker second. You’ll learn how to apply clinical guidelines and make evidence-based management decisions through detailed explanations that go beyond just identifying the correct answer. Topics Covered: Cardiovascular risk management and pharmacotherapy Acute coronary syndrome management strategies Peripheral vascular disease evaluation and treatment Secondary hypertension workup and management Perfect for: Medical students preparing for USMLE Step 2 CK Clinical year medical students on cardiology rotations IMGs studying for board exams Anyone looking to strengthen their cardiology clinical reasoning Review the full test: https://usmle-rx.scholarrx.com/share/1do75erd2wnmg0y Free Resources: Biochemistry Course: https://usmle-rx.com/biochemistry-course/ More Rx Bricks Podcasts: https://usmle-rx.com/podcast Study Planner: https://go.usmle-rx.com/study-schedule/

Another knock against the antiplatelet/anticoagulant combo, polypills in HF, the physical exam of the future, and the problem of underpowered trials that even Bayesian analyses cannot rescue are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback Trends Study https://www.heartrhythmjournal.com/article/S1547-5271(11)00496-6/fulltext II Another knock against the Antiplatelet/Anticoagulation combination “Antiplatelet Plus Oral Anticoagulant Lowers Stroke, Raises Bleeding Risk” https://www.medscape.com/viewarticle/antiplatelet-plus-oral-anticoagulant-lowers-stroke-raises-2025a1000re0 ATIS-NVAF Trial https://jamanetwork.com/journals/jamaneurology/fullarticle/2839511 AQUATIC trial https://www.nejm.org/doi/abs/10.1056/NEJMoa2507532 III Polypill for HFrEF A Multilevel Polypill for Patients With HFrEF https://www.jacc.org/doi/10.1016/j.jacadv.2025.102195 IV The Physical Exam of the Future Point-of-Care Ultrasound https://doi.org/10.1016/j.jchf.2025.102707 V More on Underpowered Trials – GA vs Moderate Sedation in IV stroke SEGA Trial https://jamanetwork.com/journals/jamaneurology/fullarticle/2839838 Bayesian Analyses of CV Trials https://doi.org/10.1016/j.cjca.2021.03.014 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

This week we review an episode from 3 years back and delve into the world of adult congenital heart disease when we review a recent work from the ACHD team at UCSF that assesses the impact of BMI on clinical outcomes in the single ventricle adult Fontan patient. What is the cause of elevation in BMI in some Fontan patients? Is obesity the only explanation? Is BMI a modifiable risk factor for our Fontan patients and should exercise be 'prescribed' for these patients? If so prescribed, what type of exercise is best for the Fontan patient? This week's work's senior author, Dr. Anushree Agarwal, Assistant Professor of Medicine at UCSF, shares her insights into this important topic. DOI: 10.1161/JAHA.122.026732Also mentioned in today's episode is episode #222 with Dr. Dan Halpern of NYU medical center (https://www.stitcher.com/show/pediheartpediatric-cardiology-today/episode/pediheart-podcast-222-impact-of-cardiac-rehab-on-exercise-tolerance-in-the-achd-patient-206781483)

In this solo episode, Darin takes on the “beef tallow” craze that's been sweeping the wellness world — exposing the industry manipulation, environmental costs, and scientific inaccuracies behind the trend. From skincare to supplements, companies are selling animal byproducts as miracle cures — but what's really happening behind the scenes? Darin dives into the industrial rendering process, the hidden pollution of factory farming, and the false “ancestral” marketing that's convincing people to buy into a billion-dollar rebrand of waste. This episode isn't about guilt — it's about truth, awareness, and sovereignty. Because when you know how the system really works, you can choose differently.     What You'll Learn 00:00:00 – Why Darin decided to peel back the layers on the beef tallow trend 00:01:00 – What tallow actually is: industrially rendered animal fat from slaughterhouse byproducts 00:03:00 – The dirty details: high-heat rendering, bleaching, deodorizing, and chemical refining 00:06:00 – The hidden foundation of factory farming and the myth of “ancestral” sourcing 00:08:00 – The human and environmental toll of the tallow supply chain — pollution, stress, and labor exploitation 00:10:00 – Marketing manipulation: how “natural” language disguises industrial exploitation 00:12:00 – Science check: why tallow isn't nutritionally superior to seed oils 00:14:00 – The clinical data: saturated vs. polyunsaturated fats and heart health 00:16:00 – The real safety issues — prion disease, contaminants, oxidation, and hidden toxins 00:18:00 – Why skincare claims are unproven — no data shows tallow outperforms plant oils 00:20:00 – The illusion of “zero-waste”: how byproduct economics fuel more slaughter 00:22:00 – What “natural” actually costs — to the planet, animals, and human health 00:24:00 – The path forward: transparency, awareness, and choosing regenerative alternatives 00:26:00 – The SuperLife perspective: stop calling destruction natural — awareness is the first step toward change     Thank You to Our Sponsors Fatty15: Get an additional 15% off their 90-day subscription Starter Kit by going to fatty15.com/DARIN and using code DARIN at checkout. EnergyBits: 100% spirulina and chlorella tablets delivering pure food nutrition. Use code SUPERLIFE for 20% off at energybits.com.     Find More from Darin Olien: Instagram: @darinolien Podcast: SuperLife Podcast Website: superlife.com Book: Fatal Conveniences     Key Takeaway “Let's stop calling destruction natural. When we stop buying into exploitation, we stop funding it — and that's when change begins for the animals, for the planet, and for us.”     Bibliography / Key References Meatscience.org, “Rendering 101” (industry rendering overview) FAO / Codex Alimentarius, edible fats and oils specifications (MIU, peroxide, etc.) Sölens / rendering-industry chemical supplier blogs (on refining aids, odor control) FDA/EPA dioxin/PCB in fats monitoring programs AHA/ACC (American Heart Association / American College of Cardiology) review on saturated vs unsaturated fats and cardiovascular disease PubMed articles on prion resistance to rendering Derm & cosmetic reviews on tallow/animal fats in skincare Industry & environmental NGO reports on factory farming's greenhouse gas, water, land use, manure pollution, worker conditions

We kicked off the program with four news stories and different guests on the stories we think you need to know about!The Nova Exhibition, honoring the Tribe of Nova massacre with relics and survivor stories, runs in South Boston through Oct. 21. Guest: Tal Mazor – Nova Festival Survivor What motorists need to be aware of with seeing more moose and deer on the roadways this Fall.  Guest: Martin Feehan - Deer & Moose Biologist, Wildlife Health Specialist at Massachusetts Division of Fisheries & Wildlife With the release of the Israeli hostages, we discuss the neuroscience of trauma and survival. Guest: Dr. Nicholas Wright - leading neuroscientist and adviser to the Pentagon, author of book: WARHEAD: How the Brain Shapes War and War Shapes the Brain With Halloween coming up, we discuss how watching scary movies or engaging in spooky activities like going to a haunted house, impacts your heart. Should certain people forgo getting “scared”? Guest: Dr. James Udelson - Chief of Cardiology at Tufts Medical Center

The air inside and outside your home often contains invisible pollutants, including fine particles and gases from traffic, industry, and household items, which accumulate in the spaces where you spend the most time Fine particulate matter (PM2.5), in particular, which is about 30 times smaller than a human hair, penetrates deeply into your lungs and bloodstream, where it contributes to cardiovascular strain and disease A large, randomized crossover trial published in the Journal of the American College of Cardiology found that using HEPA air filters indoors significantly lowered PM2.5 exposure and reduced systolic blood pressure Research links long-term air pollution to many serious health risks beyond heart disease, including respiratory illnesses, lung cancer, impaired childhood development, heightened infection rates, and neurological conditions Aside from installing HEPA filtration systems at home, other strategies to reduce your exposure to air pollutants include switching to nontoxic household products, ventilating wisely, filtering water, and reducing outdoor exposure on polluted days

GLP-1 use in HFrEF, left atrial posterior wall isolation during AF ablation, peri-device leaks for LAAO, new findings in post-cardiac surgery AF, and imaging before AF ablation are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Listener Feedback HYPERION trial https://www.nejm.org/doi/10.1056/NEJMoa2508170 ZENITH trial https://www.nejm.org/doi/full/10.1056/NEJMoa2415160 II GLP1 Use in HFrEF Effects of GLP-1s in Patients With HFrEF https://doi.org/10.1016/j.jchf.2025.102573 FIGHT Study https://jamanetwork.com/journals/jama/fullarticle/2540402 FIGHT Study Post-hoc Analysis https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.14862 Substudy of EXSCEL Trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.041659 III LA Posterior Wall Isolation Saga Failure of PW Wall Isolation by PFA with Epicardial Mapping https://doi.org/10.1016/j.jacep.2025.08.017 IV Peridevice Leaks After LAAO IMPRESSION LAAC Study https://doi.org/10.1016/j.jacep.2025.08.014 V Post Cardiac Surgery AF Monitoring of New-Onset AF After CABG https://jamanetwork.com/journals/jama/fullarticle/2839710 PACES trial https://clinicaltrials.gov/study/NCT04045665 VI TEE vs ICE Before AF ablation ICE vs TEE Study https://jamanetwork.com/journals/jamacardiology/fullarticle/2839370 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

This week we review a recent work from the "Women In Pediatric Cardiology" group which is a 4 year old initiative to help lift up women pediatric cardiologists through the fostering of connections and also via mentorship programs. Why did this program develop and what are the most pressing issues affecting female pediatric cardiologists? What are the best solutions to help address gender inequities in our field? We speak with two co-authors of this week's work, Drs. Sarah Ford of Brown University and Kristin Laraja of University of Massachussetts. For those interested in participating in their work, feel free to email  Pediheart@gmail.com and your information will be passed along to the authors. DOI: 10.1007/s00246-024-03576-9

In this episode, Dr. Lisa Howley, Director of the Fetal Cardiology Program at Children's Minnesota, discusses the biggest challenges and innovations shaping fetal and pediatric cardiology, including disparities in prenatal detection, the growing adult congenital population, and the promise of AI and telehealth in expanding access to care.

In this episode of HeartTalk, host Melanie Lawson is joined by MedAxiom's Joel Sauer, MBA, executive vice president of Consulting, and Karen Wilson, MHA, vice president of Member Services, to explore the complexity of subspecialty performance metrics in cardiovascular care. The conversation focuses on how MedAxiom's MedAxcess data tool helps identify meaningful differences in cardiology subspecialties—revealing that “one size fits all” approaches often fall short. They emphasize the importance of deeper data participation and interpretation to build more accurate, fair, and actionable insights for organizations.

In this powerful kickoff to a collaborative series with the AHA Women in Cardiology (WIC) Committee, CardioNerds (Dr. Apoorva Gangavelli, Dr. Gurleen Kaur, and Dr. Jenna Skowronski) explore the evolving landscape of women in advanced heart failure and transplant cardiology, featuring insights from two inspiring leaders in the field. Dr. Mariell Jessup, Chief Science and Medical Officer of the American Heart Association, reflects on her decades-long journey in heart failure cardiology, from navigating early career barriers to becoming a trailblazer in clinical leadership and research. Dr. Nosheen Reza, an advanced heart failure and transplant cardiologist at the University of Pennsylvania, shares how Dr. Jessup's pioneering work has inspired her own career and shaped her approach to mentorship, advocacy, and academic development. Together, they discuss the systemic challenges women continue to face, the importance of sponsorship, and the evolving culture within cardiology. Listeners will gain a multigenerational perspective on how far the field has come and what is still needed to ensure equity, excellence, and innovation in advanced heart failure care. Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. CardioNerds Heart Success Series PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! References DeFilippis EM, Moayedi Y, Reza N. Representation of Women Physicians in Heart Failure Clinical Practice. Card Fail Rev. 2021;7:e05. Published 2021 Mar 31. doi:10.15420/cfr.2020.31 

Join host Mellissa Middeldorp and her guests Mina Chung and Dominik Linz as they discuss this recent artle while in Atlanta at HRX Live 2025. In this trial the authors tested a telemedicine-based, village doctor–led integrated care model for atrial fibrillation in rural China, comparing it to usual care across 30 village clinics and over 1,000 patients. At 12 and 36 months, the intervention arm significantly improved adherence to integrated AF management and reduced composite rates of cardiovascular outcomes (death, stroke, heart failure admissions, AF emergency visits) versus control. Learning Objective Compare telemedicine based, village-doctor-led care to typical care for atrial fibrillation cases. Article Authors and Podcast Contributors  Article Authors Ming Chu, Shimeng Zhang, Jinlong Gong, Shu Yang, Gang Yang, Xingxing Sun, Dan Wu, Yaodongqin Xia, Jincheng Jiao, Xiafeng Peng, Zhihang Peng, Li Hong, Zhirong Wang, Mingfang Li, Gregory Y. H. Lip & Minglong Chen Podcast Contributors Melissa E. Middeldorp, MPH, PhD Mina K. Chung, MD, FHRS Dominik K Linz, MD, PhD   All relevant financial relationships have been mitigated. Host Disclosure(s): M. Middeldorp:   Nothing to disclose. ​Contributor Disclosure(s):    M. Chung: •Honoraria/Speaking/Consulting: University of Chicago, Cedars Sinai Medical Center, Asia Pacific Heart Rhythm Society, NIH, Baylor College of Medicine, Kansas City Heart Rhythm Symposium, American College of Cardiology, Geisinger Health Systems, ABIM, Academy for Continued Healthcare Learning, Mediasphere Medical, Western AF Symposium, University of Minnesota, Stanford University, Canadian Heart Rhythm Society •Research: NIH, American Heart Association •Royalty Income: Elsevier, Wolters Kluver •Officer: American Heart Association D. Linz Nothing to disclose.   Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner): S. Sailor: No relevant financial relationships with ineligible companies to disclose.

This episode covers: Cardiology This Week: A concise summary of recent studies Visceral adiposity: paradigm shift in HFpEF management Artificial Intelligence in echocardiography Milestones: ISIS-2 Host: Susanna Price Guests: Carlos Aguiar, Milton Packer, Rudolf de Boer Want to watch the episode? Go to: https://esc365.escardio.org/event/2175 Want to watch the extended interview on AI in echocardiography? Go to: https://esc365.escardio.org/event/2175?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Rudolf de Boer has declared to have potential conflicts of interest to report: the institution of Rudolf de Boer has received research grants and/or fees from Alnylam, AstraZeneca, Abbott, Bristol-Myers Squibb, NovoNordisk, and Roche; Rudolf de Boer has had speaker engagements with and/or received fees from and/or served on an advisory board for Abbott, AstraZeneca, Bristol Myers Squibb, NovoNordisk, Roche, and Zoll; Rudolf de Boer received travel support from Abbott and NovoNordisk. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Milton Packer has declared to have potential conflicts of interest to report: 89bio, Abbvie, Actavis, Altimmune, Alnylam, Amarin, Amgen, Ardelyx, ARMGO, AstraZeneca, Attralus, Biopeutics, Boehringer Ingelheim, Caladrius, Casana, CSL Behring, Cytokinetics, Daiichi Sankyo, Imara, Lilly, Medtronic, Moderna, Novartis, NovoNordisk, Pharmacocosmos, Regeneron, Roche, Salamandra. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Susanna Price Guest: Rudolf de Boer Want to watch that extended interview on AI in echocardiography? Go to: https://esc365.escardio.org/event/2175?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors.  This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Rudolf de Boer has declared to have potential conflicts of interest to report: the institution of Rudolf de Boer has received research grants and/or fees from Alnylam, AstraZeneca, Abbott, Bristol-Myers Squibb, NovoNordisk, and Roche; Rudolf de Boer has had speaker engagements with and/or received fees from and/or served on an advisory board for Abbott, AstraZeneca, Bristol Myers Squibb, NovoNordisk, Roche, and Zoll; Rudolf de Boer received travel support from Abbott and NovoNordisk. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

In this episode, Dr. Lisa Howley, Director of the Fetal Cardiology Program at Children's Minnesota, discusses the biggest challenges and innovations shaping fetal and pediatric cardiology, including disparities in prenatal detection, the growing adult congenital population, and the promise of AI and telehealth in expanding access to care.

Podcast summary of articles from the August 2025 edition of the Journal of Emergency Medicine from the American Academy of Emergency Medicine.  Topics include pediatric sedation, trauma triage, SVT medications, antibiotics in surgery, levothyroxine overdose, and animal bites.  Guest speaker is Dr. Cory Ohradzansky. 

Cardiologist and author Eric Topol discusses the science of longevity, why the key to healthy aging is prevention, and the perils of a fixation on reversing ageing. This podcast is intended for healthcare professionals only. To read a transcript or to comment, visit https://www.medscape.com/author/bob-harrington Super Agers: An Evidence-Based Approach to Longevity https://www.simonandschuster.com/books/Super-Agers/Eric-Topol/9781668067666 Wellderly study https://www.scripps.edu/science-and-medicine/translational-institute/translational-research/genomic-medicine/wellderly/ Lotte Bjerre Knudsen https://erictopol.substack.com/p/lotte-bjerre-knudsen-the-scientist Organ aging signatures in the plasma proteome track health and disease https://doi.org/10.1038/s41586-023- Deep Medicine https://drerictopol.com/portfolio/deep-medicine/ You may also like: Hear John Mandrola, MD, give a summary and his perspective on the top cardiology news each week, on This Week in Cardiology https://www.medscape.com/twic Questions or feedback, please contact news@medscape.net

Breast artery calcification is an incident finding on routine screening mammograms, and reflects an artery change. It has been associated with an increased risk of cardiovascular disease and CV events. Learn from guest Heather Johnson, MD, MS, MMM, how the finding can lead to improved risk reduction measures and improved patient outcomes. PCNA Heart Healthy Toolbox: https://pcna.net/resource/reducing-cv-risk-heart-healthy-toolbox/See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

With Allan Sniderman, McGill University, Montreal - Canada.  Link to European Heart Journal Editorial, by Allan Sniderman, Michael J. Pencina and George Thanassoulis Link to European Heart Journal Paper

Vidcast:  https://www.instagram.com/p/DPa5RHQADaY/Just out.  The American College of Cardiology is urging one and all adults and their medical teams to include the test for general body and cardiovascularinflammation in the annual testing battery.  That test is the high sensitivity C-Reactive Protein or hsCRP.  The hsCRP test measures low grade body inflammation.  Elevated test numbers predict the untimely occurrence of heart attacks, strokes, and death due to cardiovascular disease as predictably as bad cholesterol levels even if your cholesterol numbers are excellent.The test results are as simple as 1, 2, 3.  Less than 1 mg/L indicates low risk, 1-3 mg/L implies an average risk, and greater than 3 bodes ill for you. If your magic number is above 3, you probably already know why.  Here's chart that runs down the list: smoking; overeating with belly bulges; high cholesterol and triglycerides; high blood pressure; gum disease; and infection.The antidotes to get those hsCRP numbers down: exercise; fruits, veggies, and nuts; oily fish; and moderation of your drinking.https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2016/02/18/14/33/a-test-in-context-high-sensitivity-crp#inflammation #cardiovascular #hsCRP #screening #heartattack #stroke

Two great stories of translation science leading to beneficial drugs in terrible diseases of the heart and the Sisyphean task of predicting the need for pacing after TAVI are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Sotatercept HYPERION Trial https://www.nejm.org/doi/10.1056/NEJMoa2508170 ZENITH Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2415160 Evidence report on treatment for PAH https://icer.org/news-insights/press-releases/icer-publishes-final-evidence-report-on-treatment-for-pulmonary-arterial-hypertension/ PAH Sotatercept Editorial https://www.nejm.org/doi/full/10.1056/NEJMe2503944 II Acoramidis and ATTR Cardiomyopathy ATTRIBUTE-CM Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2305434?logout=true ATTRIBUTE-CM Analysis - Substudy https://www.jacc.org/doi/10.1016/j.jacc.2025.09.013 Tafamadis Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1805689 III Pacing After TAVI Prophylactic pacemaker after TAVI https://www.jacc.org/doi/10.1016/j.jacep.2025.07.028 PROMOTE study https://doi.org/10.1016/j.hrthm.2024.12.019 Evaluation of ESC criteria on RBBB patients undergoing TAVI https://doi.org/10.1016/j.hrthm.2024.11.030 Editorial on Heart Rhythm journal papers https://www.heartrhythmjournal.com/article/S1547-5271(25)00114-6/abstract You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

This week we review a recent multicenter, randomized trial pitting 2 different immunosuppressive therapeutic approaches against each other. How did a novel approach of everolimus + low dose tacrolimus compare to more standard MMF + standard, higher dose tacrolimus in avoidance of major adverse transplant events or complications? How did this first ever prospective trial in the pediatric heart transplantation world start and how difficult was it to perform in the absence of corporate or NIH support? Why can these data help inform FDA labelling for this novel approach and why is this important? Dr. Kevin Daly of Boston Children's Hospital shares his deep insights into this work this week!DOI: 10.1001/jama.2025.14338

Kaylin and Sharmin were joined by UCLA Cardiology fellows, Drs. Rachel Ohman and Angela Duvalyan, to discuss a case of a 49 year old woman with acute chest pain. Angela Duvalyan, MD is a second year Cardiology Fellow at University of California, Los Angeles (UCLA). Her clinical interests include interventional cardiology, medical education, and clinical… Read More »Episode 422: WDx #38: Clinical Unknown with UCLA Cardiology fellows

On this episode of JHLT: The Podcast, the Digital Media Editors invite author Dr. Ayumi Goda, from the Kyorin University Hospital in Tokyo, Japan, to discuss her team's paper, “Prevalence of occult HFpEF and age-specific efficacy of passive leg raise in pulmonary hypertension.” The discussion explores: How clinical observations led to the idea for a study on whether the passive leg raise could unmask occult HFpEF The potential diagnostic value of the passive leg raise in differing patient populations Age-specific cutoffs that may influence what kind of testing to use in clinical practice For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt. Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

Join Dr. Salim Virani as he explores global trends in cardiovascular disease, including shifting risk factors, emerging therapies, and prevention strategies. From disparities in care to the promise of primordial and even pre-primordial prevention, this conversation highlights what nurses and other healthcare professionals can do to improve heart health worldwide.Cleveland Clinic study on risk factors: https://pubmed.ncbi.nlm.nih.gov/35504796/ More information and resources can be found here: https://gcnlf.pcna.net/See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Global issues that impact cardiovascular health include access to, and continuity of, care for migrant workers, as well as rising temperatures in both rural and urban environments. Nurse Practitioner and researcher Daniel Smith, PhD, AGPCNP-BC, CNE, FAAN, shares strategies to help improve cardiovascular disease prevention and management to help every patient everywhere have improved outcomes.Related resources:Global Cardiovascular Nursing Leadership Forum: gcnlf.netCE course: https://pcna.net/course/rural-and-environment-health-a-cross-roads/See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Host Doug Stephan and Dr. Ken Kronhaus of Lake Cardiology (352-735-1400) cover a number of topics affecting our health. First up, Doug and Dr. Ken discuss the biggest news stories in the medical world, starting with a targeted itch-relief for the various types of bee/wasp/hornet stings, raising the question of what is in bee/hornet/wasp venom that causes pain, itching, as well as the more severe allergic reactions that can lead to anaphylaxis. Next up, new research linking prenatal exposure to acetaminophen (like in Tylenol) with Autism and ADHD and why some medical professionals are pushing back. Then, Doug and Dr. Ken continue the pain-reliever conversation and the benefits of routinely taking low-dose Aspirin, but the importance that a routine like this should be done under a doctor's supervision as there can be adverse effects if you are not someone that needs to be taking low-dose Aspirin regularly. Moving on, the focus shifts to brain injuries and how it affects young athletes, college-age and younger, with early neuron loss and CFE's. It's a finding that highlights long-term risk associated with sports, like football and soccer, leading to new guidelines for player safety and concussion protocols. More warnings on pregnancy and cannabis use, as use has climbed due to wider legalization and social acceptance, with many turning to marijuana to curb morning sickness and pregnancy pain symptoms. Lastly, new research explains a phenomenon how exercise suppresses appetite through a previously-unknown molecular pathway, questioning why bugs bite us, and the latest on the screwworm.  Website: GoodDayHealthrShow.com Social Media: @GoodDayNetworks

Navigating Food, Body Image, and GLP-1 Medications: An Interview with Robyn L. Goldberg, RDN, CEDS-C Therapists are seeing more clients struggling with confusing medical advice, new medications, and diet culture messages that impact their relationship with food and body. In this conversation, Curt and Katie talk with Robyn L. Goldberg, RDN, CEDS-C about how therapists can examine their own biases, support clients navigating restrictive medical guidance, and encourage healthier, more intuitive approaches to eating. About Our Guest: Robyn L. Goldberg, RDN, CEDS-C Robyn began her career at Cedars-Sinai Medical Center in Los Angeles as the in-patient dietitian in the Department of Cardiology. Over the last twenty-eight years she has developed her own private practice in Los Angeles, CA. She is a contributing author and is a nationally and internationally known registered dietitian nutritionist. She has been quoted in The New York Times, The Huffington Post, and Vogue. She has been on national television as the eating disorder expert on The Insider. Robyn is the author of The Eating Disorder Trap: A Guide for Clinicians and Loved Ones, Co-author of the online course Your Recovery Resource, and the host of The Eating Disorder Trap Podcast. Key Takeaways for Therapists Therapists must examine their own food and body biases to avoid unintentional harm to clients. Many physicians have minimal training in dietetics and may give inadequate advice. Clients can advocate for themselves in medical settings, including refusing to be weighed. GLP-1 medications may reduce appetite but can cause malnutrition, fatigue, and bone/muscle loss. Intuitive eating offers a path back to a healthier, more trusting relationship with food. For full show notes and transcript: mtsgpodcast.com Join the Modern Therapist Community Linktree: https://linktr.ee/therapyreimagined Creative Credits Voice Over by DW McCann Music by Crystal Grooms Mangano

With David Erlinge and Sasha Koul, Lund University, Lund - Sweden Read the European Heart Journal paper Read the European Heart Journal editorial

A bold trial in valvular heart disease, a CV prevention trial whose message is humility, VTE dogma challenged, more news on oral GLP-1 agonists, and a few public service announcements are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I DOUBLE-CHOICE: Minimalist Approach to TAVI May Be as Good as Standard of Care https://www.medscape.com/viewarticle/double-choice-minimalist-approach-tavi-may-be-good-standard-2025a1000pp7 Patient & Physician Perspectives on CV Risk https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.124.011837 II KP Vaccinate Trial KP Vaccinate Trial https://evidence.nejm.org/doi/full/10.1056/EVIDoa2500208 IAMI trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.057042 Increasing Flu Vaccinations in Patients With Chronic Disease https://jamanetwork.com/journals/jama/fullarticle/2824956 MI FREEE Trial https://www.nejm.org/doi/full/10.1056/NEJMsa1107913 III Hi PRO Trial Apixaban for Extended Treatment of VTE https://www.nejm.org/doi/full/10.1056/NEJMoa2509426 Recurrent VTE in Patients with Provoked VTE https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/226140 IV Oral GLP-1 Agonists ATTAIN 1 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2511774 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

This week we review a recent report of the use of phenoxybenzamine for the reduction of SVR in children undergoing congenital heart surgery in India. How does this agent work and what might be the advantage versus other agents like nitroprusside or milrinone which are more commonly used? How does the cost of this agent (or phentolamine) compare with newer agents? We speak with Dr. Rohit Loomba of Lurie Children's Hospital. For those interested, in addition to working as a critical care cardiologist, Dr. Loomba is also a noted cardiac morphologist and his wonderful videos can be seen at the following web address:https://www.youtube.com/@Talking_HeartsToday's paper:DOI: 10.4103/jpbs.jpbs_868_25

In this powerful episode of Keeping Abreast, Dr. Jenn Simmons sits down with cardiologist Dr. Jack Wolfson to challenge the conventional wisdom on heart health. Together, they unpack the failures of mainstream cardiology, the risks of statins, and why true healing comes from addressing root causes—not masking symptoms with pharmaceuticals.From nutrition and stress management to environmental toxins and community support, Dr. Wolfson and Dr. Jenn explore the real drivers of cardiovascular health. They also discuss how COVID-19 reshaped the landscape of heart disease and why women face unique risks too often ignored in conventional medicine.This conversation is essential listening for anyone questioning the pill-for-every-ill approach, seeking practical steps for prevention, or wanting to reclaim ownership of their heart health.In This Episode, You Will Learn:Why cardiovascular disease remains the #1 killer worldwideHow pharmaceuticals often miss the root causeThe truth about statins and their limited benefitsThe central role of nutrition in heart healthHow stress and emotional health impact the heartWhy toxins in food, water, and air can drive diseaseThe dangers of rigid medical guidelinesThe overlooked link between breast cancer and heart diseaseWhy community and relationships protect cardiovascular healthHow women's unique risks demand a new approach

Message our hosts, Kieran and Jose.Season 3 of The Animal Heartbeat is all about the Veterinary Cardiology Icons - those who walk among us as legends of the veterinary cardiology world.In Episode 7 of the Icons series, Prof John Bonagura joins our hosts, Jose and Kieran, to discuss how we can advance our echocardiographic skills in animals. Echocardiography is a fundamental tool for clinicians and researchers, something we use every day to infirm decision making for our patients. But is one echo the same as the next? Can we do better to improve our accuracy of diagnosis, and is there a role for standardised echo guidelines? John discusses his career spanning experience of echocardiography, from M-mode to speckle tracking techniques and using real-time 4D volumes, and updates us on the progress of the joint ACVIM-ASE guidelines for 2D echo in animals, upcoming in 2026.Listen with us as Dr Bonagura shares his perspectives and takes a deep-dive on echo for the veterinary cardiologist.

More trials at ESC, including PARACHUTE HF, DAPA ACT HF-TIMI 68, AMALFI, and a super-interesting modeling study of when to start oral anticoagulants in AF, are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I PARACHUTE HF First Evidence of Treatment Benefit in Chagas Heart Failure https://www.medscape.com/viewarticle/first-evidence-treatment-benefit-chagas-heart-failure-2025a1000oem PARACHUTE-HF https://www.jacc.org/doi/10.1016/j.jchf.2024.05.021 II SGLT2i Early Initiation — DAPA ACT HF-TIMI 68 Trial Trial Data Support In-Hospital Initiation of SGLT2 Inhibitors for Heart Failure https://www.medscape.com/viewarticle/trial-data-support-hospital-initiation-sglt2-inhibitors-2025a1000o5q DAPA ACT HF-TIMI 68 https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.076575 III AMALFI Trial of AF Screening Remote ECG Screening Ups Atrial Fibrillation Detection ‘Modestly' https://www.medscape.com/viewarticle/remote-ecg-screening-ups-atrial-fibrillation-detection-2025a1000myx AMALFI Trial https://jamanetwork.com/journals/jama/article-abstract/2838482 STROKESTOP Trial https://www.thelancet.com/article/S0140-6736(21)01637-8/fulltext LOOP Trial 10.1016/S0140-6736(21)01698-6 External Link IV Finding that Sweet Spot of Stroke Risk Threshold for Starting DOAC therapy Stroke Risk Threshold for non-Vitamin K Antagonist OAC in AF https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.125.012090 Variations in Rates of Stroke Across Patients With AF https://www.ahajournals.org/doi/10.1161/circulationaha.116.024057 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

This week we replay an episode from 2 years ago on postoperative ectopic atrial tachycardia (EAT) following congenital heart surgery in children. Are there risk factors for this arrhythmia and are any modifiable? What is the 'go to' therapy used by the electrophysiologists at Children's LA for the acute and chronic treatment of this arrhythmia in the postoperative period? Is the presence of EAT in a postoperative congenital heart patient a marker for a worse outcome? These are amongst the questions posed to Children's of Los Angeles pediatric electrophysiologist, Dr. Jonathan Uniat. ·         DOI: 10.1007/s00246-022-03068-8

More from ESC including: Valvular HD guidelines, a new drug class for HTN, myosin inhibition in HCM, vericiguat, and digoxin are the topic discussed by John Mandrola, MD. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I New European Valvular Heart Disease Guidelines 2025 ESC/EACTS Guidelines for the management of valvular heart disease  https://doi.org/10.1093/eurheartj/ehaf194 Debate: Does Asymptomatic Aortic Stenosis Warrant Early Intervention? https://exp.medscape.com/debates/does-asymptomatic-aortic-stenosis-warrant-early-intervention/ Surgical Ablation of Atrial Fibrillation during Mitral-Valve Surgery https://www.nejm.org/doi/full/10.1056/NEJMoa1500528 Surgical ablation of atrial fibrillation: a systematic review and meta-analysis https://doi.org/10.1093/europace/eux336 II  New Drug for Resistant HTN Baxdrostat: A 'Game Changer' for Hypertension? https://www.medscape.com/viewarticle/baxdrostat-game-changer-hypertension-2025a1000mz7 Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension https://www.nejm.org/doi/full/10.1056/NEJMoa2507109 Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension https://www.nejm.org/doi/10.1056/NEJMoa2501440 III HCM News at ESC New Trials Clarify Role of Myosin Inhibitors for Hypertrophic Cardiomyopathy https://www.medscape.com/viewarticle/new-trials-clarify-role-myosin-inhibitors-hypertrophic-2025a1000myv MAPLE HCM https://www.nejm.org/doi/full/10.1056/NEJMoa2504654 SEQUOIA HCM https://www.nejm.org/doi/10.1056/NEJMoa2401424 ODYSSEY HCM https://www.nejm.org/doi/full/10.1056/NEJMoa2505927 IV Vericiguat at ESC New Data Said to Support Vericiguat as Standard Therapy for Heart Failurehttps://www.medscape.com/viewarticle/new-data-said-support-vericiguat-standard-therapy-heart-2025a1000mz9 VICTOR https://doi.org/10.1016/S0140-6736(25)01665-4 VICTORIA https://www.nejm.org/doi/full/10.1056/NEJMoa1915928 An individual participant data analysis of the VICTORIA and VICTOR trials https://doi.org/10.1016/S0140-6736(25)01682-4 V More on Digoxin RATE AF substudy https://doi.org/10.1002/ejhf.70022 Main RATE-AF trial https://jamanetwork.com/journals/jama/fullarticle/2774407 Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis https://doi.org/10.1016/S0140-6736(14)61373-8 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

The big beta-blocker story from ESC, dual pathway therapy with aspirin and OAC, stopping OAC after successful AF ablation, and DANCAVAS II trial are the topics John Mandrola, MD, discusses on this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback This Week in Cardiology Podcast – August 29 https://www.medscape.com/viewarticle/1002877 II The Big Beta-blocker Story from ESC Beta-Blockers Post-MI: A Clear Clinical Message https://www.medscape.com/viewarticle/beta-blockers-post-mi-clear-clinical-message-2025a1000mz0 REBOOT https://www.nejm.org/doi/full/10.1056/NEJMoa2504735 BETAMI-DANBLOCK https://www.nejm.org/doi/abs/10.1056/NEJMoa2505985 REDUCE AMI https://www.nejm.org/doi/10.1056/NEJMoa2401479 CAPITAL RCT https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0199347 Post Hoc Analysis From REBOOT Trial https://eurointervention.pcronline.com/article/effect-of-beta-blocker-withholding-or-withdrawal-after-myocardial-infarction-without-reduced-ejection-fraction-on-ischaemic-events-a-post-hoc-analysis-from-the-reboot-trial Beta-Blockers After MI With Mildly Reduced Ejection Fraction https://doi.org/10.1016/S0140-6736(25)01592-2 CAPRICORN 10.1016/S0140-6736(00)04560-8 External Link BHAT https://jamanetwork.com/journals/jama/fullarticle/370103 ISIS 1 https://pubmed.ncbi.nlm.nih.gov/2873379/ III Aspirin and OAC Combination Clearly Dangerous Aspirin Plus Oral Anticoagulants Raises Mortality, Bleeding https://www.medscape.com/viewarticle/aspirin-plus-oral-anticoagulants-raises-mortality-bleeding-2025a1000nam AQUATIC https://www.nejm.org/doi/full/10.1056/NEJMoa2507532 AFIRE https://www.nejm.org/doi/full/10.1056/NEJMoa1904143 EPIC CAD https://www.nejm.org/doi/10.1056/NEJMoa2407362 OAC-ALONE  https://pubmed.ncbi.nlm.nih.gov/30586700/ IV Stop or Continue OAC after Successful AF Ablation ALONE-AF https://jamanetwork.com/journals/jama/fullarticle/2838294 OCEAN trial protocol https://doi.org/10.1016/j.ahj.2017.12.007 V DANCAVAS II Trial DANCAVAS II https://doi.org/10.1093/eurheartj/ehaf704 DANCAVAS I https://www.nejm.org/doi/full/10.1056/NEJMoa2208681 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net